Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...

Earnings call CAREL Industries reported FY 2025 revenue of EUR 629 million, up 8.7% YoY (10.6% organic), with Q4 organic growth accelerating to 16.9%. Adjusted EBITDA margin reached 20%, and net ...